Adjuvant Chemotherapy With or Without Intercalated Icotinib

NANot yet recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2025

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Icotinib

Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity

DRUG

Placebo

Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity

OTHER

chemotherapy

Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER